Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 84,300 shares, a drop of 49.6% from the December 31st total of 167,300 shares. Approximately 1.0% of the company’s shares are sold short. Based on an average daily volume of 67,100 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC increased its position in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Stock Performance

Shares of ATHE stock traded up $1.66 during trading hours on Thursday, hitting $4.57. 22,983,248 shares of the company were exchanged, compared to its average volume of 1,413,567. Alterity Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.87. The company has a 50 day simple moving average of $2.64 and a two-hundred day simple moving average of $1.80.

Analyst Upgrades and Downgrades

Separately, Maxim Group upped their price target on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.